The use of genomic tools for the molecular understanding of breast cancer and to guide personalized medicine

Drug Discovery Today

Volumn 13, Issue 11-12, 2008, Pages 481-487

  Foekens, John A ^a   Wang, Yixin ^b   Martens, John W M ^a   Berns, Els M J J ^a   Klijn, Jan G M ^a  

^a JOSEPHINE NEFKENS INSTITUTE   (Netherlands)

^b JOHNSON AND JOHNSON   (United States)

Author keywords

[No Author keywords available]

Indexed keywords

ESTROGEN RECEPTOR; MATRIX METALLOPROTEINASE; MESSENGER RNA; TISSUE INHIBITOR OF METALLOPROTEINASE;

BIOINFORMATICS; BREAST CANCER; CANCER RESEARCH; COMPARATIVE GENOMIC HYBRIDIZATION; DNA METHYLATION; DNA MICROARRAY; GENE EXPRESSION PROFILING; GENE MUTATION; HIGH THROUGHPUT SCREENING; PROGNOSIS; REVIEW; SINGLE NUCLEOTIDE POLYMORPHISM; TREATMENT PLANNING;

ANTINEOPLASTIC AGENTS; BREAST NEOPLASMS; DRUG DELIVERY SYSTEMS; DRUG DESIGN; FEMALE; GENE EXPRESSION REGULATION, NEOPLASTIC; GENOMICS; HUMANS; OLIGONUCLEOTIDE ARRAY SEQUENCE ANALYSIS;

EID: 44649096321     PISSN: 13596446     EISSN: None     Source Type: Journal    
DOI: 10.1016/j.drudis.2008.03.003     Document Type: Review

References (100)

1. Cariati M., and Purushotham A.D. Stem cells and breast cancer. Histopathology 52 (2008) 99-107
2. Stingl J., and Caldas C. Molecular heterogeneity of breast carcinomas and the cancer stem cell hypothesis. Nat. Rev. Cancer 7 (2007) 791-799
3. Perou C.M., et al. Molecular portraits of human breast tumours. Nature 406 (2000) 747-752
4. Sorlie T., et al. Gene expression patterns of breast carcinomas distinguish tumor subclasses with clinical implications. Proc. Natl. Acad. Sci. U. S. A. 98 (2001) 10869-10874
5. West R.B., et al. Determination of stromal signatures in breast carcinoma. PLoS Biol. 3 (2005) e187
6. Gruvberger S., et al. Estrogen receptor status in breast cancer is associated with remarkably distinct gene expression patterns. Cancer Res. 61 (2001) 5979-5984
7. Sotiriou C., et al. Gene expression profiling in breast cancer: understanding the molecular basis of histologic grade to improve prognosis. J. Natl. Cancer Inst. 98 (2006) 262-272
8. Bertucci F., et al. Gene expression profiling shows medullary breast cancer is a subgroup of basal breast cancers. Cancer Res. 66 (2006) 4636-4644
9. Hedenfalk I., et al. Gene-expression profiles in hereditary breast cancer. N. Engl. J. Med. 344 (2001) 539-548
10. Chin K., et al. Genomic and transcriptional aberrations linked to breast cancer pathophysiologies. Cancer Cell 10 (2006) 529-541
11. van de Vijver M.J., et al. A gene-expression signature as a predictor of survival in breast cancer. N. Engl. J. Med. 347 (2002) 1999-2009
12. Chang H.Y., et al. Robustness, scalability, and integration of a wound-response gene expression signature in predicting breast cancer survival. Proc. Natl. Acad. Sci. U. S. A. 102 (2005) 3738-3743
13. Winter S.C., et al. Relation of a hypoxia metagene derived from head and neck cancer to prognosis of multiple cancers. Cancer Res. 67 (2007) 3441-3449
14. Liu R., et al. The prognostic role of a gene signature from tumorigenic breast-cancer cells. N. Engl. J. Med. 356 (2007) 217-226
15. Yu K., et al. A molecular signature of the Nottingham prognostic index in breast cancer. Cancer Res. 64 (2004) 2962-2968
16. Wang Y., et al. Gene-expression profiles to predict distant metastasis of lymph-node-negative primary breast cancer. Lancet 365 (2005) 671-679
17. Van 't Veer L.J., et al. Gene expression profiling predicts clinical outcome of breast cancer. Nature 415 (2002) 530-536
18. Kang Y., et al. Breast cancer bone metastasis mediated by the Smad tumor suppressor pathway. Proc. Natl. Acad. Sci. U. S. A. 102 (2005) 13909-13914
19. Smid M., et al. Genes associated with breast cancer metastatic to bone. J. Clin. Oncol. 24 (2006) 2261-2267
20. Minn A.J., et al. Lung metastasis genes couple breast tumor size and metastatic spread. Proc. Natl. Acad. Sci. U. S. A. 104 (2007) 6740-6745
21. Minn A.J., et al. Genes that mediate breast cancer metastasis to lung. Nature 436 (2005) 518-524
22. Jansen M.P., et al. Molecular classification of tamoxifen-resistant breast carcinomas by gene expression profiling. J. Clin. Oncol. 23 (2005) 732-740
23. Hannemann J., et al. Changes in gene expression associated with response to neoadjuvant chemotherapy in breast cancer. J. Clin. Oncol. 23 (2005) 3331-3342
24. Rouzier R., et al. Breast cancer molecular subtypes respond differently to preoperative chemotherapy. Clin. Cancer Res. 11 (2005) 5678-5685
25. Chang J.C., et al. Gene expression profiling for the prediction of therapeutic response to docetaxel in patients with breast cancer. Lancet 362 (2003) 362-369
26. Hess K.R., et al. Pharmacogenomic predictor of sensitivity to preoperative chemotherapy with paclitaxel and fluorouracil, doxorubicin, and cyclophosphamide in breast cancer. J. Clin. Oncol. 24 (2006) 4236-4244
27. Gyorffy B., et al. Prediction of doxorubicin sensitivity in breast tumors based on gene expression profiles of drug-resistant cell lines correlates with patient survival. Oncogene 24 (2005) 7542-7551
28. Dupuy A., and Simon R.M. Critical review of published microarray studies for cancer outcome and guidelines on statistical analysis and reporting. J. Natl. Cancer Inst. 99 (2007) 147-157
29. Michiels S., et al. Prediction of cancer outcome with microarrays: a multiple random validation strategy. Lancet 365 (2005) 488-492
30. Massague J. Sorting out breast-cancer gene signatures. N. Engl. J. Med. 356 (2007) 294-297
31. Simon R. Development and evaluation of therapeutically relevant predictive classifiers using gene expression profiling. J. Natl. Cancer Inst. 98 (2006) 1169-1171
32. Ransohoff D.F. Rules of evidence for cancer molecular-marker discovery and validation. Nat. Rev. Cancer 4 (2004) 309-314
33. Buyse M., et al. Validation and clinical utility of a 70-gene prognostic signature for women with node-negative breast cancer. J. Natl. Cancer Inst. 98 (2006) 1183-1192
34. Desmedt C., et al. Strong time dependence of the 76-gene prognostic signature for node-negative breast cancer patients in the TRANSBIG multicenter independent validation series. Clin. Cancer Res. 13 (2007) 3207-3214
35. Foekens J.A., et al. Multicenter validation of a gene expression-based prognostic signature in lymph node-negative primary breast cancer. J. Clin. Oncol. 24 (2006) 1665-1671
36. Hu Z., et al. The molecular portraits of breast tumors are conserved across microarray platforms. BMC Genomics 7 (2006) 96
37. Consortium M., et al. The MicroArray Quality Control (MAQC) project shows inter- and intraplatform reproducibility of gene expression measurements. Nat. Biotechnol. 24 (2006) 1151-1161
38. Sotiriou C., and Piccart M.J. Taking gene-expression profiling to the clinic: when will molecular signatures become relevant to patient care?. Nat. Rev. Cancer 7 (2007) 545-553
39. Paik S., et al. A multigene assay to predict recurrence of tamoxifen-treated, node-negative breast cancer. N. Engl. J. Med. 351 (2004) 2817-2826
40. Goeman J.J., et al. Testing association of a pathway with survival using gene expression data. Bioinformatics 21 (2005) 1950-1957
41. Goeman J.J., et al. A global test for groups of genes: testing association with a clinical outcome. Bioinformatics 20 (2004) 93-99
42. Vogelstein B., and Kinzler K.W. Cancer genes and the pathways they control. Nat. Med. 10 (2004) 789-799
43. Tinker A.V., et al. The challenges of gene expression microarrays for the study of human cancer. Cancer Cell 9 (2006) 333-339
44. O'Shaughnessy J.A. Molecular signatures predict outcomes of breast cancer. N. Engl. J. Med. 355 (2006) 615-617
45. Weigelt B., et al. Breast cancer metastasis: markers and models. Nat. Rev. Cancer 5 (2005) 591-602
46. Fan C., et al. Concordance among gene-expression-based predictors for breast cancer. N. Engl. J. Med. 355 (2006) 560-569
47. Yu J.X., et al. Pathway analysis of gene signatures predicting metastasis of node-negative primary breast cancer. BMC Cancer 7 (2007) 182
48. Lamb J., et al. A mechanism of cyclin D1 action encoded in the patterns of gene expression in human cancer. Cell 114 (2003) 323-334
49. Huang E., et al. Gene expression phenotypic models that predict the activity of oncogenic pathways. Nat. Genet. 34 (2003) 226-230
50. Bild A.H., et al. Oncogenic pathway signatures in human cancers as a guide to targeted therapies. Nature 439 (2006) 353-357
51. Jänicke F., et al. Randomized adjuvant chemotherapy trial in high-risk, lymph node-negative breast cancer patients identified by urokinase-type plasminogen activator and plasminogen activator inhibitor type 1. J. Natl. Cancer Inst. 93 (2001) 913-920
52. Look M.P., et al. Pooled analysis of prognostic impact of urokinase-type plasminogen activator and its inhibitor PAI-1 in 8377 breast cancer patients. J. Natl. Cancer Inst. 94 (2002) 116-128
53. Andreasen P.A., et al. The urokinase-type plasminogen activator system in cancer metastasis: a review. Int. J. Cancer 72 (1997) 1-22
54. Kanehisa M., and Goto S. KEGG: kyoto encyclopedia of genes and genomes. Nucleic Acids Res. 28 (2000) 27-30
55. Zhang Y., et al. Distinct roles of two structurally closely related focal adhesion proteins, alpha-parvins and beta-parvins, in regulation of cell morphology and survival. J. Biol. Chem. 279 (2004) 41695-41705
56. Slamon D.J., et al. Studies of the HER-2/neu proto-oncogene in human breast and ovarian cancer. Science 244 (1989) 707-712
57. Kallioniemi O.P., et al. ERBB2 amplification in breast cancer analyzed by fluorescence in situ hybridisation. Proc. Natl. Acad. Sci. U. S. A. 89 (1992) 5321-5325
58. Kallioniemi A., et al. Detection and mapping of amplified DNA sequences in breast cancer by comparative genomic hybridisation. Proc. Natl. Acad. Sci. U. S. A. 91 (1994) 2156-2160
59. Isola J.J., et al. Genetic aberrations detected by comparative genomic hybridization predict outcome in node-negative breast cancer. Am. J. Pathol. 147 (1995) 905-911
60. Pollack J.R., et al. Genome-wide analysis of DNA copy-number changes using cDNA microarrays. Nat. Genet. 23 (1999) 41-46
61. Zhang Y., et al. Genome-wide assessment of DNA copy number alterations in conjunction with gene expression profiling identifies DNA amplification loci that predict distant recurrence in lymph node-negative (LNN) primary breast cancer patients. San Anontio Breast Cancer Conference (2006) Abstract 32
62. Calin G.A., and Croce C.M. Chromosomal rearrangements and microRNAs: a new cancer link with clinical implications. J. Clin. Invest. 117 (2007) 2059-2066
63. Calin G.A., and Croce C.M. MicroRNA signatures in human cancers. Nat. Rev. Cancer 6 (2006) 857-866
64. Bartel D.P. MicroRNAs: genomics, biogenesis, mechanism, and function. Cell 116 (2004) 281-297
65. Caldas C., and Brenton J.D. Sizing up miRNAs as cancer genes. Nat. Med. 11 (2005) 712-714
66. Iorio M.V., et al. MicroRNA gene expression deregulation in human breast cancer. Cancer Res. 65 (2005) 7065-7070
67. Blenkiron C., et al. MicroRNA expression profiling of human breast cancer identifies new markers of tumour subtype. Genome Biol. 8 (2007) R214
68. Ma L., et al. Tumour invasion and metastasis initiated by microRNA-10b in breast cancer. Nature 449 (2007) 682-688
69. Zhang L., et al. microRNAs exhibit high frequency genomic alterations in human cancer. Proc. Natl. Acad. Sci. U. S. A. 103 (2006) 9136-9141
70. Calin G.A., et al. Ultraconserved regions encoding ncRNAs are altered in human leukemias and carcinomas. Cancer Cell 12 (2007) 215-229
71. Volinia S., et al. A microRNA expression signature of human solid tumors defines cancer gene targets. Proc. Natl. Acad. Sci. U. S. A. 103 (2006) 2257-2261
72. Negrini M., et al. MicroRNAs in human cancer: from research to therapy. J. Cell Sci. 120 Pt 11 (2007) 1833-1840
73. Sjöblom T., et al. The consensus coding sequences of human breast and colorectal cancers. Science 314 (2006) 268-274
74. Wood L.D., et al. The genomic landscapes of human breast and colorectal cancers. Science (2007)
75. Hunter D.J., et al. A genome-wide association study identifies alleles in FGFR2 associated with risk of sporadic postmenopausal breast cancer. Nat. Genet. 39 (2007) 870-874
76. Stacey S.N., et al. Common variants on chromosomes 2q35 and 16q12 confer susceptibility to estrogen receptor-positive breast cancer. Nat. Genet. 39 (2007) 865-869
77. Yeager M., et al. Genome-wide association study of prostate cancer identifies a second risk locus at 8q24. Nat. Genet. 39 (2007) 645-649
78. Zanke B.W., et al. Genome-wide association scan identifies a colorectal cancer susceptibility locus on chromosome 8q24. Nat. Genet. 39 (2007) 989-994
79. Broderick P., et al. A genome-wide association study shows that common alleles of SMAD7 influence colorectal cancer risk. Nat. Genet. 39 (2007) 1315-1317
80. Easton D.F., et al. Genome-wide association study identifies novel breast cancer susceptibility loci. Nature 447 (2007) 1087-1093
81. Herman J.G., and Baylin S.B. Gene silencing in cancer in association with promoter hypermethylation. N. Engl. J. Med. 349 (2003) 2042-2054
82. Jones P.A., and Baylin S.B. The epigenomics of cancer. Cell 128 (2007) 683-692
83. Esteller M. Cancer epigenomics: DNA methylomes and histone-modification maps. Nat. Rev. Genet. 8 (2007) 286-298
84. Lujambio A., and Esteller M. CpG island hypermethylation of tumor suppressor microRNAs in human cancer. Cell Cycle 6 (2007) 1455-1459
85. Saito Y., et al. Specific activation of microRNA-127 with downregulation of the proto-oncogene BCL6 by chromatin-modifying drugs in human cancer cells. Cancer Cell 9 (2006) 435-443
86. Lujambio A., et al. Genetic unmasking of an epigenetically silenced microRNA in human cancer cells. Cancer Res. 67 (2007) 1424-1429
87. Esteller M. Epigenetic gene silencing in cancer: the DNA hypermethylome. Hum. Mol. Genet. 16 Spec No 1 (2007) R50-R59
88. Potti A., et al. Genomic signatures to guide the use of chemotherapeutics. Nat. Med. 12 (2006) 1294-1300
89. Hsu D.S., et al. Pharmacogenomic strategies provide a rational approach to the treatment of cisplatin-resistant patients with advanced cancer. J. Clin. Oncol. 25 (2007) 4350-4357
90. Huang F., et al. Identification of candidate molecular markers predicting sensitivity in solid tumors to dasatinib: rationale for patient selection. Cancer Res. 67 (2007) 2226-2238
91. Nevins J.R., and Potti A. Mining gene expression profiles: expression signatures as cancer phenotypes. Nat. Rev. Genet. 8 (2007) 601-609
92. Lamb J., et al. The Connectivity Map: using gene-expression signatures to connect small molecules, genes, and disease. Science 313 (2006) 1929-1935
93. Lamb J. The Connectivity Map: a new tool for biomedical research. Nat. Rev. Cancer 7 (2007) 54-60
94. Hieronymus H., et al. Gene expression signature-based chemical genomic prediction identifies a novel class of HSP90 pathway modulators. Cancer Cell 10 (2006) 321-330
95. Wei G., et al. Gene expression-based chemical genomics identifies rapamycin as a modulator of MCL1 and glucocorticoid resistance. Cancer Cell 10 (2006) 331-342
96. Tomlins S.A., et al. Integrative molecular concept modeling of prostate cancer progression. Nat. Genet. 39 (2007) 41-51
97. Pujana M.A., et al. Network modeling links breast cancer susceptibility and centrosome dysfunction. Nat. Genet. 39 (2007) 1338-1349
98. Araujo R.P., et al. Proteins, drug targets and the mechanisms they control: the simple truth about complex networks. Nat. Rev. Drug Discov. 6 (2007) 871-880
99. Petricoin E.F., et al. The blood peptidome: a higher dimension of information content for cancer biomarker discovery. Nat. Rev. Cancer 6 (2006) 961-967
100. Petricoin III E.F., et al. Phosphoprotein pathway mapping: Akt/mammalian target of rapamycin activation is negatively associated with childhood rhabdomyosarcoma survival. Cancer Res. 67 (2007) 3431-3440